Tango Therapeutics (TNGX) Enterprise Value (2020 - 2026)

Tango Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$157.8 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 27.18% year-over-year to -$157.8 million; the TTM figure through Mar 2026 stood at -$157.8 million (up 27.18% YoY), while the FY2025 annual figure was -$112.7 million, up 56.73% from the prior year.
• Enterprise Value for Q1 2026 stood at -$157.8 million, down from -$112.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$58.8 million in Q3 2025, with the low at -$449.9 million in Q1 2022.
• The 5-year median for Enterprise Value is -$216.7 million (2025), against an average of -$219.7 million.
• Peak annual rise in Enterprise Value reached 79.98% in 2022, while the deepest fall reached 583.81% in 2022.
• Tango Therapeutics' Enterprise Value stood at -$60.5 million in 2022, then declined by 11.08% to -$67.2 million in 2023, then tumbled by 287.39% to -$260.5 million in 2024, then jumped by 56.73% to -$112.7 million in 2025, then sank by 40.03% to -$157.8 million in 2026.
• Business Quant data shows TNGX's Enterprise Value at -$157.8 million in Q1 2026, -$112.7 million in Q4 2025, and -$58.8 million in Q3 2025.